Literature DB >> 6252316

High-pressure liquid chromatographic determination of ranitidine, a new H2-receptor antagonist, in plasma and urine.

G W Mihaly, O H Drummer, A Marshall, R A Smallwood, W J Louis.   

Abstract

An assay is described for the determination of a new H2-receptor antagonist, ranitidine, and its desmethyl metabolite in human plasma and urine. Alkalinized plasma or urine was extracted with methylene chloride, the organic phase was evaporated, and the reconstituted residue was analyzed by high-pressure liquid chromatography using a reversed-phase column. Two other identified metabolites of ranitidine, the S-oxide and N-oxide, were separated chromtographically from both ranitidine and the desmethyl metabolite. However, these metabolites could not be quantitative due to poor analytical recovery and interference from endogenous components. The sensitivity limits were 5 ng/ml for ranitidine and 15 ng/ml for desmethylranitidine. Plasma samples from two volunteers who were given oral ranitidine (0.1, 0.2, and 0.4 mg/kg) at 1-week intervals were assayed. Peak levels of 30--130 ng/ml were achieved between 40 and 120 min after dosage, followed by an elimination half-life of 2.9-3.9 hr. Plasma levels of ranitidine were still detectable at 8 hr but were below the sensitivity of the assay by 24 hr. Plasma levels of the desmethyl metabolite were seldom above the threshold sensitivity of the assay. Urinary excretion of unmetabolized ranitidine accounted for 77% of the administered dose, whereas only 4% appeared as desmethylranitidine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6252316     DOI: 10.1002/jps.2600691008

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers.

Authors:  W Mück; W Wingender; M Seiberling; E Woelke; K D Rämsch; J Kuhlmann
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy.

Authors:  P J Prichard; D B Jones; N D Yeomans; G W Mihaly; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

4.  Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics.

Authors:  L K Webster; G W Mihaly; D B Jones; R A Smallwood; J A Phillips; F J Vajda
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  High dose of antacid (Mylanta II) reduces bioavailability of ranitidine.

Authors:  G W Mihaly; A T Marino; L K Webster; D B Jones; W J Louis; R A Smallwood
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-09

6.  Pharmacokinetic studies of cimetidine and ranitidine before and after treatment in peptic ulcer patients.

Authors:  G W Mihaly; D B Jones; J A Anderson; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

Review 7.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

8.  Pharmacokinetics of the H2- receptor antagonist ranitidine in man.

Authors:  J J McNeil; G W Mihaly; A Anderson; A W Marshall; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

10.  Kinetics of rate controlled rectally administered ranitidine to male volunteers.

Authors:  H De Bree; A G De Boer
Journal:  Pharm Weekbl Sci       Date:  1987-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.